| Literature DB >> 33214628 |
Arturas Grauslys1, Marie M Phelan1, Caroline Broughton2, Paul B Baines3,4, Rebecca Jennings5, Sarah Siner5, Stephane C Paulus2,6, Enitan D Carrol7,8,9.
Abstract
Sepsis, defined as life-threatening organ dysfunction caused by infection is difficult to distinguish clinically from infection or post-operative inflammation. We hypothesized that in a heterogeneous group of critically ill children, there would be different metabolic profiles between post-operative inflammation, bacterial and viral infection and infection with or without organ dysfunction. 1D 1H nuclear magnetic resonance spectra were acquired in plasma samples from critically ill children. We included children with bacterial (n = 25) and viral infection (n = 30) and controls (n = 58) (elective cardiac surgery without infection). Principal component analysis was used for data exploration and partial least squares discriminant analysis models for the differences between groups. Area under receiver operating characteristic curve (AUC) values were used to evaluate the models. Univariate analysis demonstrated differences between controls and bacterial and viral infection. There was excellent discrimination between bacterial and control (AUC = 0.94), and viral and control (AUC = 0.83), with slightly more modest discrimination between bacterial and viral (AUC = 0.78). There was modest discrimination (AUC = 0.73) between sepsis with organ dysfunction and infection with no organ dysfunction. In critically ill children, NMR metabolomics differentiates well between those with a post-operative inflammation but no infection, and those with infection (bacterial and viral), and between sepsis and infection.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33214628 PMCID: PMC7677384 DOI: 10.1038/s41598-020-77319-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Key characteristics of patient cohort.
| Bacterial infection (N = 25) | Viral infection (N = 30) | Controls (N = 58) | |
|---|---|---|---|
| Age, median (range), months | 28.4 (8.2–103.4) | 9.3 (0.8–156.6) | 16.2 (0.12–197.2) |
| Male, No. (%) | 14 (56) | 19 (63) | 29 (50) |
| MODS, No. (%) | 18 (72) | 7 (23) | 1 (1.7) |
| LOS on PICU, median (range), days | 6.5 (0.5–26.6) | 3.9 (1.7–45.6) | 1.3 (0.57–29.4) |
| Deaths No | 1 | 0 | 1 |
| Pathogens | Klebsiella pneumoniae (2) Methicillin Resistant Staphylococcus aureus (1) Neisseria meningitidis (11) Pseudomonas aeruginosa (2) Stenotrophomonas maltophilia (1) Streptococcus pneumoniae (4) Streptococcus pyogenes (4) | Adenovirus (2) Coronavirus (2) Herpes Simplex Virus (1) Influenza A (3) Respiratory Syncytial Virus (13) Rhinovirus ( 9) Varicella Zoster Virus ( 1) (1 patient had more than 1 virus) |
MODS multiple organ dysfunction patient count, LOS length of stay, PICU paediatric intensive care unit.
Figure 1Metabolite abundance comparison. Each comparison is shown in column (C control, DV definite viral, DB definite bacterial). The numbers and colours denote log ratio of group means in statistically significant comparisons only (t-test, alpha = 0.05). Red means increased in DB:C or DV:C, purple lower in DB. DV relative to C or lower in DB relative to DV.
Figure 2Sparse partial least squares discriminant analysis (a) scores plot of model including DB (N = 25) and C (N = 58); (b) scores plot of model including DV (30) and C (N = 58); the most contributing metabolite signals (VIP scores); (c) C and DB; (d) C and DV. Associated AUC = 0.94 in DB-C and 0.83 in DV-C. DB—definite bacterial, DV – definite viral, C control, VIP variable importance score.
Figure 3PLS-DA (a) scores plot of model including DB (N = 25) and DV (N = 30) samples. (b) Most contributing metabolite signals (VIP scores). Associated AUC = 0.78.
Figure 4Comparison of metabolic profiles for MOD, no MOD and control cohorts. (a) Metabolite abundance comparison. Each comparison is shown in column (C—control, Yes—multiple organ dysfunction, No—no multiple organ dysfunction). The numbers and colours denote log ratio of group means in statistically significant comparisons only (t test, alpha = 0.05). Mean log ratios of MOD-positive and MOD negative group metabolic profiles with controls.
Figure 5Metabolite profiles were investigated by pairwise comparisons of cohorts with and without MOD and fitting a PLS-DA model for selection of discriminating metabolites. The results show (a) scores plot (1 component) of model including MOD positive patients with infection (blue) (N = 25) vs MOD negative patients with infection (red) (N = 30). (b) Metabolite importance (VIP) plot. Associated AUC = 0.73.
Metabolites reported in the literature in published studies on infection and sepsis, that were also differentially increased or decreased in our cohort.
| Metabolite IDa | Mickiewicz 2013[ | Mickiewicz 2015[ | Mickiewicz 2015[ | Kamisoglu 2015[ | Venet 2017[ | Lin 2009 [ | Izquierdo-Garcia 2011[ | Xu 2008 [ | Liu 2016 [ | Fanos 2014 [ | Our study | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 00452 | * | |||||||||||
| 2-Hydroxybutyric acid | 00008 | * | + | – | + | + | ||||||
| 2-Hydroxyisobutyric acid | 00729 | * | – | |||||||||
| 2-Hydroxy-3-methylbutyric acid | 00407 | * | - | + | ||||||||
| 2-Methylglutaric acid | 00422 | * | ||||||||||
| 2-Methylhippuric acid | 11723 | * | ||||||||||
| Ketoleucine | 00695 | * | – | |||||||||
| 3-Hydroxybutyric acid | 00357 | * | + | + | ||||||||
| 3-Hydroxyisovaleric acid | 00754 | * | – | |||||||||
| 3-Methyl-2-oxovaleric acid | 00491 | – | ||||||||||
| Acetic acid | 00042 | * | + | + | + | – | ||||||
| Acetoacetic acid | 00060 | + | + | |||||||||
| Acetone | 01659 | * | + | – | ||||||||
| Adipic acid | 00448 | * | + | |||||||||
| 00161 | * | + | * | + | + | – | ||||||
| Oxoglutaric acid | 00208 | * | ||||||||||
| 00517 | * | – | * | + | ||||||||
| Argininosuccinic acid | 00052 | * | ||||||||||
| 00168 | * | |||||||||||
| Betaine | 00043 | * | * | + | ||||||||
| 00062 | * | * | ||||||||||
| Choline | 00097 | + | * | |||||||||
| Citric acid | 00094 | * | * | + | * | |||||||
| Citrulline | 00904 | * | ||||||||||
| Creatine | 00064 | * | + | * | + | |||||||
| Creatinine | 00562 | * | * | + | ||||||||
| Dimethylamine | 00087 | – | ||||||||||
| Ethanol | 00108 | * | ||||||||||
| Formic acid | 00142 | – | – | + | ||||||||
| D-Glucose | 00122 | * | – | * | + | + | ||||||
| 00148 | * | – | * | – | ||||||||
| Glutamate-Glutamine | ||||||||||||
| 00641 | * | * | – | |||||||||
| Glutathione | 00125 | * | ||||||||||
| Glycerol | 00131 | * | ||||||||||
| Glycine | 00123 | * | + | |||||||||
| Hippuric acid | 00714 | * | ||||||||||
| 00177 | * | + | ||||||||||
| Hypoxanthine | 00157 | * | * | |||||||||
| Indolelactic acid | 00671 | * | ||||||||||
| Indoxyl sulfate | 00682 | * | ||||||||||
| inosine | 00195 | * | ||||||||||
| Isobutyric acid | 01873 | * | + | – | ||||||||
| 00172 | * | * | * | * | ||||||||
| 00190 | * | * | + | * | + | – | ||||||
| 00687 | * | * | – | |||||||||
| 00182 | * | + | ||||||||||
| Malic acid | 00744 | * | ||||||||||
| D-Mannose | 00169 | – | ||||||||||
| Methanol | 01875 | * | – | |||||||||
| 00696 | * | * | ||||||||||
| myo-Inositol | 00211 | * | + | |||||||||
| O-Acetylcarnitine | 00201 | * | + | |||||||||
| Acetylcholine | 00895 | + | * | |||||||||
| Ornithine | 00214 | * | * | + | ||||||||
| 00159 | * | + | * | + | ||||||||
| Phosphoryl-choline | 01565 | * | ||||||||||
| 00162 | + | * | * | |||||||||
| Propylene glycol | 01881 | - | - | |||||||||
| Pyroglutamic acid | 00267 | * | ||||||||||
| Pyruvic acid | 00243 | * | - | |||||||||
| 00187 | * | |||||||||||
| Suberic acid | 00893 | * | ||||||||||
| Succinic acid | 00254 | * | ||||||||||
| Taurine | 00251 | * | + | + | ||||||||
| 00167 | * | - | * | |||||||||
| 00158 | * | * | + | |||||||||
| Urea | 00294 | * | + | |||||||||
| 00883 | - | * | * | + |
Metabolites levels increase or decrease with sepsis/infection as indicated by + or –, respectively. Metabolites associated with sepsis/infection but levels not specified (or differentially attributed) are indicated by *.
†All numbers preceded by ‘HMDB00’.